

January 14, 2026

To
National Stock Exchange of India Limited
Exchange Plaza, Plot C-1, Block- G
Bandra Kurla Complex, Bandra (East)
Mumbai – 400051

NSE Scrip: VILINBIO

Sub: Revised Outcome of Board Meeting held on January 10, 2026

** Further to the Outcome of the Board Meeting dated January 10, 2026, the Company is filing the Revised Outcome due to omission of few points pertaining to the Extra-ordinary General Meeting, the details of which are furnished below:*

Dear Sir / Madam,

In compliance with Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, we hereby inform you that the Board of Directors of the Company met today i.e. Saturday, January 10, 2026 at the Registered Office of the Company and transacted the following:

1. Increase in Authorised Share Capital to Rs.25,00,00,000/- (Rupees Twenty-Five Crores) divided into 2,50,00,000 (Two Crores Fifty Lakhs) Equity Shares of Rs.10/- (Rupees Ten Only) each. Consequently, the Capital Clause of the Memorandum of Association of the Company is to be altered, subject to approval of the Members in the General Meeting.
2. The Board is in the process of identifying potential companies for acquisition.
3. Issuance of up to 13,00,000 (Thirteen Lakhs Only) Equity Shares of Face Value of Rs.10/- on Preferential Basis to the selected group of investors, at the Issue Price of Rs.26/- (Rupees Twenty Six Only) Per Equity Share, aggregating to an amount of Rs.3,38,00,000/- (Rupees Three Crores Thirty Eight Lakhs Only) subject to approval of the Members in the ensuing General Meeting and Regulatory Authorities.

Pursuant to Regulation 30(2) of the SEBI Listing Regulations read with Circular CIR/CFD/CMD/4/2015 dated September 9, 2015 the relevant details have been enclosed herewith as **Annexure – A**.

4. Considered and approved convening an Extra-ordinary General Meeting of the Members of the Company on Monday, February 9, 2026 at 4:00 P.M. through Video-Conferencing (VC) / Other Audio-Visual Means (OAVM)
5. Appointed Mr. Kashinath Sahu, Practicing Company Secretary (CP No. 4807) as the Scrutinizer for conducting the E-Voting Process for the Extra-ordinary General Meeting.

Registered Office: Plot No. 43, H. No. 8-2-269/S/43, 2nd Floor, Sagar Co-op Housing Society Ltd, Road No. 2, Banjara Hills Khairatabad, Hyderabad – 500034

Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar – 247667

Tel No: 040- 79618843

CIN: L24230TG2005PLC046689

GST: 36AACCV1433D1ZR E-

mail: cs@vilinbiomed.co.in

Website: www.vilinbio.com

6. Approved the E-Voting facility through CDSL E-Voting Platform, to facilitate the Members of the Company to cast their votes electronically and finalised the E-Voting Dates:

Sl No	Particulars	Details
1	E-Voting Start Date and Time	February 5, 2026 (09:00 A.M. IST)
2	E-Voting End Date and Time	February 8, 2026 (05:00 P.M. IST)
3	Cut-off Date for E-Voting	February 2, 2026

7. Considered and noted resignation of Mr. Girish Muktevi as Independent Director of the Company, who has resigned due to his personal commitments and that there are no other material reasons. The required disclosure is enclosed as **Annexure – B**.

The Board Meeting commenced at 5:00 P.M. and concluded at 8:40 P.M.

Kindly take the above information on record.

For Vilin Bio Med Limited

Madhusudhan Yadamakanti Reddy
Managing Director
DIN: 02874260

Annexure – A

Sl No	Particulars	Details																												
1	Type of Securities proposed to be issued	Equity Shares																												
2	Type of Issuance	Preferential Allotment																												
3	Total number of securities proposed to be issued or total amount for which the securities will be issued (approximately)	13,00,000 (Thirteen Lakhs Only)																												
4	Name of Investors	1. AMN Ventures LLP – 6,30,000 Equity Shares 2. Enspire Institute of Professional Studies LLP – 6,70,000 Equity Shares																												
5	Post-allotment of Securities - Outcome of the Subscription, Issue Price / Allotted Price (in case of convertibles), number of investors	Post-Allotment SHP <table border="1" data-bbox="775 840 1506 1136"> <thead> <tr> <th>Category</th> <th>Number of Shares held</th> <th>%</th> <th>Number of Shares held</th> <th>%</th> </tr> </thead> <tbody> <tr> <td align="center" colspan="2">Pre</td><td align="center" colspan="3">Post</td></tr> <tr> <td>Promoters</td> <td>89,11,999</td> <td>63.89</td> <td>89,11,999</td> <td>58.44</td> </tr> <tr> <td>Non-Promoters</td> <td>50,38,001</td> <td>36.11</td> <td>63,38,001</td> <td>41.56</td> </tr> <tr> <td align="center">Total</td><td align="center">1,39,50,000</td><td align="center">100.00</td><td align="center">1,52,50,000</td><td align="center">100.00</td></tr> </tbody> </table>				Category	Number of Shares held	%	Number of Shares held	%	Pre		Post			Promoters	89,11,999	63.89	89,11,999	58.44	Non-Promoters	50,38,001	36.11	63,38,001	41.56	Total	1,39,50,000	100.00	1,52,50,000	100.00
Category	Number of Shares held	%	Number of Shares held	%																										
Pre		Post																												
Promoters	89,11,999	63.89	89,11,999	58.44																										
Non-Promoters	50,38,001	36.11	63,38,001	41.56																										
Total	1,39,50,000	100.00	1,52,50,000	100.00																										
6	In case of Convertibles - intimation on conversion of Securities or on lapse of the tenure of the instrument	Not Applicable																												

Annexure – B

Sl No	Particulars	Details
1	Reason for Change	Resignation of Mr. Girish Muktevi (DIN: 10709464) as Independent Director owing to his personal commitments
2	Date of Cessation	Closure of business hours of January 10, 2026
3	Brief Profile	Not applicable
4	Disclosure of relationships between Directors	Not applicable
5	Names of the Listed Entities in which the resigning Director holds Directorships, indicating the category of Directorship and Membership of the Board Committees, if any	<u>Directorship:</u> 1. Vilin Bio Med Limited - Independent Director <u>Committees:</u> 1. Audit Committee – Chairman 2. Nomination and Remuneration Committee – Member 3. Stakeholder Relationship Committee – Member
6	Information as required as per NSE Circular NSE/CML/2018/24	Not Applicable